Molbio Diagnostics Limited
MOLBIO (NSE) · MOLBIO (BSE 544866) · ISIN INE869T01028 · Medical Equipment & Supplies · Est. 2000 · listed 2026 · website
Not on any surveillance list
In Q1 FY27 (quarter to 30 June 2026, standalone), revenue was ₹399.38 cr and profit after tax ₹56.63 cr.
Quarterly results
| Quarter | Revenue | Profit after tax | EPS (₹) | Filed |
|---|---|---|---|---|
| Q1 FY27 standalone | ₹399.38 cr | ₹56.63 cr | 5.02 | 5 Sep 2026 |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 41.29% | 1.59% | 19.08% | 58.71% |
Latest filings
- Molbio Diagnostics Limited has informed the Exchange about Transcript of the Earnings Call held on September 08, 2026 in relation to the Unaudited Financial Results of the Company for the quarter ende 12 September 2026 · NSE
- Molbio Diagnostics Limited has informed the Exchange about Link of Recording 8 September 2026 · NSE
- Molbio Diagnostics Limited has informed the Exchange about Investor Presentation on the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026 8 September 2026 · NSE
- Molbio Diagnostics Limited has informed the Exchange regarding a press release dated September 07, 2026, titled "Press Release for the Quarter ended June 30, 2026.". 7 September 2026 · NSE
- Molbio Diagnostics Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026. 5 September 2026 · NSE
Other companies in Medical Equipment & Supplies
- Poly Medicure Limited
- Tarsons Products Limited
- Vasa Denticity Limited
- Fabtech Technologies Limited
- Laxmi Dental Limited
- Nureca Limited
- QMS Medical Allied Services Limited
- Fischer Medical Ventures Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 29 October 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.